Search
Candel Therapeutics Inc
CADLAdd to Watchlist
9.830USD
-0.050-0.51%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
720.12MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.51%
5 Days
+3.80%
1 Month
+16.75%
6 Months
+80.70%
Year to Date
+73.98%
1 Year
+96.99%
Key Figures
9.970Open
10.170High
1.55MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.12%Turnover Ratio
9.880Prev. Close
9.570Low
11.40MTurnover
LossP/E Static
5.22P/B
0.00%Div Yield TTM
-36.55%ROA
7.25052wk High
1.15Volume Ratio
-55.18MNet Profit
73.26MShares
-1.0092EPS TTM
-0.75Beta
-51.17%ROE
4.25052wk Low
6.07%Amplitude
100.00%Gross Margin
720.12MMarket Cap
2.89Reward/Risk
4.24%Risk Rate
TradingKey Stock Score of Candel Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Candel Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 115 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.29.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Candel Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Candel Therapeutics Inc Highlights
StrengthsRisks
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Undervalued
The company’s latest PE is -9.74, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 24.37M shares, decreasing 12.62% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 65.26K shares of this stock.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
20.286
Target Price
+95.81%
Upside Space
Candel Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Candel Therapeutics Inc Info
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Ticker SymbolCADL
CompanyCandel Therapeutics Inc
CEOTak (Paul Peter)
Websitehttps://www.candeltx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
53029.700
+187.200 (+0.35%)
29549.700
+238.300 (+0.81%)
7505.100
+33.600 (+0.45%)
15059.000
+256.000 (+1.73%)
69449.000
+1301.000 (+1.91%)
6381.000
+28.200 (+0.44%)
68.953
+0.609 (+0.89%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4177.620
+55.710 (+1.35%)
FAQs
What is the current price of Candel Therapeutics Inc (CADL)?
The current price of Candel Therapeutics Inc (CADL) is 9.83.
What is the symbol of Candel Therapeutics Inc?
The ticker symbol of Candel Therapeutics Inc is CADL.
What is the 52-week high of Candel Therapeutics Inc?
The 52-week high of Candel Therapeutics Inc is 7.25.
What is the 52-week low of Candel Therapeutics Inc?
The 52-week low of Candel Therapeutics Inc is 4.25.
What is the market capitalization of Candel Therapeutics Inc?
The market capitalization of Candel Therapeutics Inc is 720.12M.
Is Candel Therapeutics Inc (CADL) currently rated as Buy, Hold, or Sell?
According to analysts, Candel Therapeutics Inc (CADL) has an overall rating of Buy, with a price target of 20.29.
What is the Earnings Per Share (EPS TTM) of Candel Therapeutics Inc (CADL)?
The Earnings Per Share (EPS TTM) of Candel Therapeutics Inc (CADL) is -0.72.